Yawning as a dose-dependent side effect of treatment with escitalopram

Bostezos como efecto secundario dependiente de la dosis del tratamiento con escitalopram

Dear Editor

The neurobiological processes involved in yawning are complex. Yawning is controlled by the dopaminergic and oxytocinergic systems. These systems activate the cholinergic system, which may also be activated by the serotonergic system. On the neuroanatomical level, yawning involves motor centres of the brainstem (V, VII, IX, X, XI, and XII) and the spinal cord, which are controlled by the paraventricular nucleus of the hypothalamus. A group of oxytocin neurons situated in the paraventricular region of the paraventricular nuclei and extending towards the hippocampus facilitate yawning, in conjunction with the locus coeruleus and the spinal cord. Yawning results when these neurons are stimulated by dopamine or dopaminergic agonists, histamine, or oxytocin; it is inhibited by opioids and γ-aminobutyric acid. The serotonergic system also facilitates yawning. Serotonergic activation and dopaminergic inhibition may work together in the event of yawning. In addition, the serotonergic system also interacts with the cholinergic system, since the serotonin reuptake inhibitor citalopram (Lu 10-171) favours yawning induced by physostigmine (a cholinergic antagonist). Yawning is also indicative of numerous pathological processes that generally go unnoticed in clinical practice (intracranial hypertension, migraine, cerebrovascular accidents, frontal lobe tumours, temporal lobe epilepsy, progressive supranuclear palsy, multiple sclerosis, thalamotomy, liver and kidney failure, opiate withdrawal, etc.). Some drugs, such as dopaminergic agonists or serotonin reuptake inhibitors, may provoke yawning as a side effect (Table 1). According to some drug safety reports, paroxetine may also cause yawning (5 cases).

We present the case of a woman aged 37 who was first monitored by the psychiatric department in 2010 due to obsessive thoughts and egodystonic compulsions. The rest of her medical history was anodyne. She met DSM IV-TR criteria for obsessive-compulsive disorder, and doctors decided to treat her with escitalopram in increasing doses over a 3-week period until reaching 20 mg/day. The patient was not taking any other drugs. Treatment initially resulted in clinical improvement and the patient reported frequent yawning as a side effect, with episodes occurring regularly throughout the day. This was the only side effect, and it had very little repercussion on the different aspects of the patient’s life. After escitalopram was reduced to 15 mg/day, yawning frequency decreased and had disappeared completely after 10 days. At present, the patient remains stable on a dose of 10 mg/day, with good level of tolerance and no adverse effects.

This 37-year-old woman therefore experienced yawning as a dose-dependent side effect of escitalopram. This case coincides with a published case involving citalopram. Yawning is a side effect of both non-selective and selective serotonin reuptake inhibitors (SSRIs). The literature contains only a few cases due to their low frequency and/or non-detection of this sign. Yawning does not seem to be sex-related (Table 1). Yawning is an easily observable clinical sign that may be an adverse drug effect or an alarm sign indicating central nervous system disease or other neuropsychiatric disorders. However, yawning is underinvestigated and rarely examined in the clinical setting.

Early detection of the temporal relationship between onset of excessive yawning and treatment with serotonergic agents allows doctors to offer simple remedies such as decreasing dosage or changing the treatment. This serves to prevent unnecessary healthcare spending on more complex complementary tests and also lets doctors rule out serious diseases.

Table 1  Clinical cases of yawning after treatment with serotonin reuptake inhibitors.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Reuptake inhibition</th>
<th>No. sex</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipramine</td>
<td>NA and 5HT</td>
<td>1 M</td>
<td>McLean et al., 1983</td>
</tr>
<tr>
<td>Clomipramine</td>
<td>NA and 5HT</td>
<td>4:2 M/2F</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:1 M/1 F</td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Selective for 5HT</td>
<td>1 M</td>
<td>Cohen et al., 1983</td>
</tr>
<tr>
<td>Sertraline</td>
<td>Selective for 5HT</td>
<td>1 M</td>
<td>Beale et al., 2000</td>
</tr>
<tr>
<td>Citalopram</td>
<td>Selective for 5HT</td>
<td>1 M</td>
<td>Pal et al., 2009</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>NA and 5HT</td>
<td>1 M</td>
<td>Chen et al., 2009</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>5HT and de NA</td>
<td>2:1 M/1 F</td>
<td></td>
</tr>
<tr>
<td>Escitalopram</td>
<td>Selective for 5HT</td>
<td>2 F</td>
<td>Gutierrez-Alvarez, 2007</td>
</tr>
</tbody>
</table>

NA: noradrenaline; 5HT: serotonin; DA: dopamine; M: male; F: female.

References


C. Roncero*, M. Mezzatesta-Gava, L. Grau-López, C. Daigre
Centro de Atención y Seguimiento de Drogodependencias Vall d’Hebron, Servicio de Psiquiatría, Hospital Universitario Vall d’Hebron-Agencia de Salud Pública de Barcelona, CIBERSAM, Barcelona, Spain

*Corresponding author.
E-mail address: croncero@vhebron.net
(C. Roncero.)